Arovella Therapeutics (ALA) Corporate presentation summary

Investment highlights and platform overview

• CAR-iNKT platform enables development of multiple future therapies, including for blood cancers, solid tumours, and autoimmune diseases.

• Structurally differentiated, next-generation cell therapy with off-the-shelf manufacturing and healthy donor starting material.

• FDA IND accepted for lead program; phase 1 trial expected to start September 2026 with preliminary data in early 2027.

• Platform allows multiple doses per batch, reducing cost and improving scalability.

Leadership and financials

• Leadership team has expertise in drug development, cell therapy manufacturing, translational research, and clinical trial delivery.

• Market capitalization of $78.58 million as of August 2026, with $14.4 million cash on hand at June 30, 2026.

• Major shareholders include Biotech Capital Management (10.72%) and Richard John Mann (5.67%).

• Share price ranged from $0.059 to $0.100 over the past year.

Technology and differentiation

• Traditional CAR-T therapies are patient-specific, time-intensive, and costly, with manufacturing taking 3-4 weeks.

• CAR-iNKT cells offer an allogeneic, off-the-shelf solution, enabling treatment within one week and serving multiple patients per batch.

• iNKT cells bridge innate and adaptive immunity, have a strong safety profile, and do not cause graft versus host disease.

• CAR-iNKT cells can attack tumours via multiple mechanisms, infiltrate solid tumours, and modulate the tumour microenvironment.